Pirbright Institute Develops New Tools to Track Key Immune Cells in Pigs, Accelerating Vaccine Research

How Pirbright's New Tools Unlock Pig Immune Responses

Researchers at The Pirbright Institute have developed new laboratory tools that allow scientists to identify and study a critical group of immune cells in pigs for the first time. These cells, known as T follicular helper (Tfh) cells, play a central role in helping the body produce high-quality antibodies after vaccination or infection. The breakthrough, published in the Journal of Immunology, could significantly accelerate the design and testing of vaccines for both animals and humans.

Tfh cells are essential for long-lasting immunity and are increasingly recognized as a key indicator of successful vaccine responses. While these cells have been extensively studied in humans and mice, little was known about their counterparts in pigs—despite pigs being widely used as a preclinical model for infectious disease research. The main obstacle was the lack of tools to identify and analyze porcine Tfh cells.

To overcome this, the Pirbright team created a new antibody that targets CXCR5, a hallmark marker of Tfh cells, along with a novel reagent to detect PD-1, another key molecule associated with these cells. Using these tools, they successfully identified distinct populations of Tfh cells and their regulatory counterparts, T follicular regulatory (Tfr) cells, in blood, lymph nodes, spleen, and tonsils from healthy pigs.

The researchers found that tonsils contained significantly more Tfh cells than other lymphoid organs, suggesting they are a key site for generating antibody responses. In contrast, neighboring lymph nodes had higher numbers of Tfr cells, which help control immune responses and prevent autoimmunity. Laboratory experiments confirmed that pig Tfh cells function as expected, effectively supporting B cell survival, proliferation, and differentiation into antibody-producing plasma cells. This provides valuable new methods for assessing vaccine effectiveness in pigs and could improve the evaluation of vaccine candidates against a range of viral and bacterial diseases.

Why Pig Immunology Matters for the $100B Vaccine Industry

Why Pig Immunology Is a Strategic Asset for Vaccine Developers

Pigs are not just livestock—they are one of the most important preclinical models for human infectious disease research. Their immune system closely resembles that of humans, making them valuable for testing vaccines before human trials. However, the lack of tools to study pig Tfh cells has been a bottleneck. This breakthrough removes that obstacle, giving researchers a way to measure vaccine-induced immunity in pigs with far greater precision. For context, the global vaccine market is valued at over $100 billion, and animal health vaccines represent a growing segment as livestock producers seek to reduce antibiotic use and combat emerging diseases.

The Competitive Edge for Pirbright and UK Research

The Pirbright Institute is a world-leading center for research on viral diseases of farm animals. By developing these novel reagents, Pirbright has positioned itself at the forefront of veterinary immunology. Other research institutions and pharmaceutical companies working on vaccines for diseases like African swine fever, foot-and-mouth disease, and influenza will now be able to license or replicate these tools. This could accelerate vaccine pipelines and strengthen the UK's role as a hub for animal health innovation. The study's publication in the Journal of Immunology also signals high scientific credibility, which may attract further funding and partnerships.

Implications for Livestock Producers and Animal Health Companies

For livestock producers, better vaccines mean healthier herds, lower mortality, and reduced economic losses from disease outbreaks. African swine fever alone has caused billions in losses across Asia and Europe in recent years. For animal health companies like Zoetis, Boehringer Ingelheim, and Merck Animal Health, this research could lead to more effective vaccines and new diagnostic tools. The ability to monitor Tfh responses may also help companies demonstrate vaccine efficacy more convincingly to regulators, potentially shortening approval timelines. In the medium term (6–24 months), expect increased R&D activity around pig vaccines, with possible licensing deals for the new tools.

What to Watch: From Lab to Market

The immediate next step is for other researchers to adopt these tools and validate them across different pig populations and disease models. If the tools prove robust, they could become standard in vaccine trials. Long term (2–5 years), this could contribute to a new generation of vaccines that provide longer-lasting immunity, reducing the need for booster shots in both animals and humans. However, challenges remain: scaling up production of the reagents, ensuring reproducibility across laboratories, and translating findings from pigs to humans. The researchers' claim that pig Tfh cells share characteristics with human cells is promising but requires further verification in clinical settings.

What This Means for Vaccine Developers and Livestock Producers

The most important insight: This breakthrough gives vaccine developers a new way to measure immune responses in pigs, which could shorten development timelines and improve vaccine efficacy for both animals and humans.

For executives at animal health companies and research institutions, here is what to do next:

• 0–6 months: Evaluate whether the new anti-CXCR5 antibody and PD-1 reagent can be integrated into your existing vaccine research protocols. Contact The Pirbright Institute to discuss licensing or collaboration opportunities.
• 6–24 months: If you are developing vaccines for swine diseases (e.g., African swine fever, PRRS), consider using these tools to monitor Tfh responses in clinical trials. This could provide stronger evidence of long-lasting immunity for regulatory submissions.
• 2–5 years: Monitor how this research influences vaccine approval standards. If Tfh response becomes a recognized correlate of protection, vaccines that demonstrate strong Tfh activation may gain a competitive advantage.

Metrics to watch: The number of peer-reviewed studies citing this methodology, licensing agreements for the new reagents, and any regulatory guidance referencing Tfh cells as a vaccine efficacy marker. Also track Pirbright's follow-up publications and whether major animal health companies announce partnerships based on this work.